A new study has found that cross-sex hormones used by transgender people to treat gender dysphoria are correlated with dramatically increased risks of stroke, heart attack, and blood clots.
The long-term risks of the drugs in gender dysphoria patients have been under-studied, with previous research focusing on women using hormone-based birth control or after menopause.
People with gender dysphoria taking hormone replacements as part of gender affirmation therapy face a substantially increased risk of serious cardiac events, including stroke, heart attack and pulmonary embolism, according to a study presented at the American College of Cardiology's Annual Scientific Session Together With the World Congress of Cardiology.